Among cancer survivors, bevacizumab, the most commonly used anticancer VEGF monoclonal antibody that inhibits angiogenesis, has been increasingly shown to be associated with risks of cardiovascular and cerebrovascular ischemia as well as bleeding events [5]. Here, VEGFA is linked to cancer.